DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,677,581 | +4.1% | 91,405 | +0.7% | 2.15% | +10.5% |
| Q2 2023 | $21,775,440 | -5.0% | 90,731 | -0.2% | 1.95% | -7.9% |
| Q1 2023 | $22,913,460 | -5.3% | 90,912 | -0.3% | 2.12% | -5.5% |
| Q4 2022 | $24,200,465 | +1.4% | 91,178 | -1.3% | 2.24% | -5.9% |
| Q3 2022 | $23,865,000 | +2.0% | 92,395 | +0.1% | 2.38% | +8.3% |
| Q2 2022 | $23,399,000 | -14.2% | 92,294 | -0.7% | 2.20% | +1.3% |
| Q1 2022 | $27,264,000 | -11.5% | 92,943 | -0.8% | 2.17% | -9.6% |
| Q4 2021 | $30,811,000 | +4.6% | 93,649 | -3.2% | 2.40% | -3.2% |
| Q3 2021 | $29,449,000 | +14.2% | 96,731 | +0.6% | 2.48% | +11.4% |
| Q2 2021 | $25,796,000 | +18.9% | 96,124 | -0.3% | 2.22% | +9.7% |
| Q1 2021 | $21,701,000 | +1.4% | 96,414 | +0.0% | 2.03% | -3.7% |
| Q4 2020 | $21,408,000 | -0.6% | 96,371 | -3.7% | 2.11% | -6.3% |
| Q3 2020 | $21,547,000 | +23.6% | 100,066 | +1.5% | 2.25% | +5.3% |
| Q2 2020 | $17,433,000 | +29.1% | 98,584 | +1.1% | 2.14% | +6.5% |
| Q1 2020 | $13,502,000 | -10.3% | 97,553 | -0.6% | 2.00% | +15.7% |
| Q4 2019 | $15,059,000 | +8.5% | 98,112 | +2.1% | 1.73% | -0.2% |
| Q3 2019 | $13,877,000 | -7.7% | 96,075 | -8.7% | 1.74% | +0.3% |
| Q2 2019 | $15,033,000 | -9.7% | 105,181 | -16.6% | 1.73% | +1.1% |
| Q1 2019 | $16,652,000 | +26.8% | 126,141 | -1.0% | 1.71% | +12.9% |
| Q4 2018 | $13,130,000 | -1.7% | 127,376 | +3.6% | 1.52% | +10.3% |
| Q3 2018 | $13,361,000 | +11.9% | 122,959 | +1.6% | 1.38% | +2.5% |
| Q2 2018 | $11,941,000 | +1.4% | 120,998 | +0.6% | 1.34% | -1.0% |
| Q1 2018 | $11,780,000 | +5.2% | 120,321 | -0.3% | 1.36% | +12.2% |
| Q4 2017 | $11,202,000 | +13.0% | 120,688 | +4.4% | 1.21% | +8.8% |
| Q3 2017 | $9,915,000 | +10.9% | 115,584 | +9.0% | 1.11% | -3.6% |
| Q2 2017 | $8,944,000 | +33.1% | 105,997 | +34.9% | 1.15% | +31.4% |
| Q1 2017 | $6,721,000 | +7.4% | 78,585 | -2.2% | 0.88% | -2.4% |
| Q4 2016 | $6,257,000 | +2.2% | 80,381 | +2.9% | 0.90% | -3.6% |
| Q3 2016 | $6,122,000 | -19.8% | 78,100 | +3.4% | 0.93% | -18.4% |
| Q2 2016 | $7,630,000 | +2.4% | 75,540 | -3.8% | 1.14% | -1.2% |
| Q1 2016 | $7,449,000 | -1.3% | 78,530 | -3.4% | 1.16% | -2.2% |
| Q4 2015 | $7,550,000 | +8.2% | 81,285 | -0.7% | 1.18% | +11.0% |
| Q3 2015 | $6,978,000 | -0.5% | 81,890 | -0.1% | 1.07% | +9.2% |
| Q2 2015 | $7,015,000 | +0.5% | 81,961 | -0.3% | 0.98% | -1.5% |
| Q1 2015 | $6,978,000 | -2.9% | 82,186 | -2.0% | 0.99% | -11.9% |
| Q4 2014 | $7,189,000 | +10.5% | 83,877 | -2.1% | 1.13% | +13.5% |
| Q3 2014 | $6,508,000 | -5.6% | 85,656 | -2.2% | 0.99% | -12.8% |
| Q2 2014 | $6,895,000 | +6.3% | 87,586 | +1.3% | 1.14% | +8.8% |
| Q1 2014 | $6,487,000 | -2.6% | 86,491 | +0.2% | 1.04% | -5.2% |
| Q4 2013 | $6,663,000 | +7.6% | 86,306 | -3.4% | 1.10% | -4.1% |
| Q3 2013 | $6,194,000 | +11.8% | 89,346 | +2.1% | 1.15% | -2.3% |
| Q2 2013 | $5,542,000 | – | 87,551 | – | 1.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |